TYRA Biosciences (NASDAQ: TYRA) insider transactions
In the twelve months to 10 November 2026, executives and directors of TYRA Biosciences reported 14 open-market sales of 552,166 shares ($10.6m) and 1 open-market purchase of 972 shares ($20,001), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 15 September 2026 | Fuhrman Alan | Chief Financial Officer | Grant or award | +951 | $9.13 | 37,115 | Form 4 |
| 15 September 2026 | Rueb Yuliya | Vice President, Finance (PAO) | Grant or award | +2,925 | $9.13 | 11,258 | Form 4 |
| 15 September 2026 | Harris Todd | President and CEO | Grant or award | +864 | $9.13 | 1,438,495 | Form 4 |
| 9 September 2026 | Verjee Rehan | Director | Open-market purchase | +972 | $20.58 | 972 | Form 4 |
| 5 May 2026 | Rueb Yuliya | Vice President, Finance (PAO) | Grant or award | +8,333 | — | 43,354 | Form 4 |
| 5 May 2026 | Ashar Bhavesh | Chief Operating Officer | Grant or award | +15,013 | — | 15,013 | Form 4 |
| 5 May 2026 | Harris Todd | President and CEO | Grant or award | +79,000 | — | 1,437,631 | Form 4 |
| 5 May 2026 | Fuhrman Alan | Chief Financial Officer | Grant or award | +20,000 | — | 36,164 | Form 4 |
| 5 May 2026 | Warner Douglas J | Chief Medical Officer | Grant or award | +25,000 | — | 25,000 | Form 4 |
| 26 March 2026 | Kaplan Gilla | Director | Option exercise | −53,172 | $2.25 | 81,403 | Form 4 |
| 26 March 2026 | Kaplan Gilla | Director | Returned to the company | −53,172 | $37.75 | 28,231 | Form 4 |
| 25 March 2026 | Kaplan Gilla | Director | Option exercise | +14,295 | $2.25 | 42,526 | Form 4 |
| 25 March 2026 | Kaplan Gilla | Director | Open-market sale | −14,295 | $36.97 | 28,231 | Form 4 |
| 13 March 2026 | Harris Todd | President and CEO | Grant or award | +1,463 | $9.13 | 1,358,631 | Form 4 |
| 13 March 2026 | Fuhrman Alan | Chief Financial Officer | Grant or award | +1,376 | $9.13 | 16,164 | Form 4 |
| 12 February 2026 | Bensen Daniel | Chief Discovery Officer | Open-market sale | −2,128 | $31.50 | 152,853 | Form 4 |
| 12 February 2026 | Bensen Daniel | Chief Discovery Officer | Open-market sale | −5,872 | $33.37 | 146,981 | Form 4 |
| 12 January 2026 | Bensen Daniel | Chief Discovery Officer | Open-market sale | −6,983 | $28.44 | 155,998 | Form 4 |
| 12 January 2026 | Bensen Daniel | Chief Discovery Officer | Open-market sale | −1,017 | $29.08 | 154,981 | Form 4 |
| 19 December 2025 | More Robert J | Director | Open-market sale | −10,000 | $25.00 | 3,823,425 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the TYRA Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.